Skip to content
    MDLN
    Earnings call· Dec 2025(Q4 FY25)

    Medline Q4 FY25 earnings call MDLN

    Feb 25, 2026 Source

    Executive summary

    Medline Q4 FY25 — Strong Sales Growth and Debt Reduction Post-IPO

    Medline concluded FY25 with robust sales growth and a strengthened financial position following its IPO, enabling continued strategic investments in automation, technology, and product innovation. The company successfully navigated significant tariff headwinds through mitigation efforts and pricing discipline, while also securing record new customer signings. Management remains confident in its resilient business model and long-term value creation, despite anticipating some moderation in healthcare utilization and ongoing tariff volatility.

    Highlights

    5

    • Annual net sales grew $3 billion to $28.4 billion, up 12% year-over-year (11% organically).

    • Fourth quarter net sales reached $7.8 billion, a 15% increase year-over-year.

    • Secured $2.4 billion in total new customer signings in 2025, a record year.

    • Adjusted EBITDA for the full year was $3.5 billion, up 3% versus prior year.

    • Net leverage reduced from 4.9x at the end of 2024 to 3.1x at the end of 2025 following the IPO.

    Concerns

    5

    • Fourth quarter adjusted EBITDA margin declined 160 basis points to 10% due to higher costs, including tariffs and increased headcount investments.

    • Full year adjusted EBITDA margin declined 100 basis points to 12.2% due to tariffs and business investments.

    • The net tariff impact totaled approximately $290 million for full year 2025.

    • Anticipates an incremental $200 million tariff headwind in 2026, reflecting policy prior to recent Supreme Court decisions.

    • Expects same-store sales growth to moderate slightly in 2026 due to potential impacts from OBVA, ACA, and Medicare.

    Guidance & targets

    8
    CategoryTargetConfidence
    Full-year 2026 organic sales growth
    8% to 9%
    high materiality
    High
    Full-year 2026 Adjusted EBITDA
    $3.5 billion to $3.6 billion
    high materiality
    High
    Full-year 2026 net interest expense
    $575 million and $625 million
    medium materiality
    Medium
    Full-year 2026 Capital expenditures
    approximately $500 million
    medium materiality
    High
    Full-year 2026 effective tax rate
    17.5% and 19.5%
    medium materiality
    Medium
    Full-year 2026 tax distributions to NCI
    $250 million to $350 million
    medium materiality
    Medium
    Full-year 2026 fully diluted shares outstanding
    approximately 1.4 billion
    low materiality
    High
    Annual new prime vendor closings
    $1 billion
    medium materiality
    High

    Segment performance

    16
    SegmentRevenueYoYQoQMargin
    Medline Brands
    Net sales for the fourth quarter.
    		$3.7 billion12%——
    Medline Brands
    Net sales for the full year.
    		$13.7 billion10%——
    Surgical Solutions (Medline Brands)
    Net sales for the fourth quarter, driven by strong growth in surgical kitting and other OR products.
    		$1.7 billion12%——
    Surgical Solutions (Medline Brands)
    Net sales for the full year, with a 3 percentage point contribution from the Microtek Surgical Solutions acquisition.
    		$6.2 billion13%——
    Front Line Care (Medline Brands)
    Net sales for the fourth quarter, with strong volume in personal care, home medical equipment, Ready Care, and Wound Care.
    		$1.8 billion11%——
    Front Line Care (Medline Brands)
    Net sales for the full year, with a 1 percentage point contribution from the Coloplast skincare acquisition.
    		$6.5 billion7%——
    Lab & Diagnostics (Medline Brands)
    Net sales for the fourth quarter, driven by existing customer demand and new customer implementations.
    		$289 million12%——
    Lab & Diagnostics (Medline Brands)
    Net sales for the full year, driven by volume growth in laboratory products.
    		$1 billion9%——
    Supply Chain Solutions
    Net sales for the fourth quarter, supported by new customer implementations and existing customer growth.
    		$4.1 billion18%——
    Supply Chain Solutions
    Net sales for the full year, creating efficiencies of scale and operating leverage.
    		$14.7 billion13%——
    U.S. Acute care
    Sales by channel for the fourth quarter, driven by new prime vendor customers and solid same-store sales growth.
    		$5.3 billion16%——
    U.S. Acute care
    Sales by channel for the full year.
    		$19.5 billion12%——
    U.S. Non-Acute
    Sales by channel for the fourth quarter, supported by strong existing customer growth and new customer signings.
    		$1.9 billion12%——
    U.S. Non-Acute
    Sales by channel for the full year.
    		$7 billion11%——
    International
    Sales by channel for the fourth quarter, driven by volume growth in Canada and Europe.
    		$537 million12%——
    International
    Sales by channel for the full year.
    		$2 billion11%——

    Operational metrics

    13
    Organic sales growth
    11%
    FY25

    Driven by strong demand from existing customers and new customer signings.

    Adjusted EBITDA margin
    10%down 160 bps YoY
    Q4 FY25

    Due to higher costs including tariffs and increased investment in headcount.

    Adjusted EBITDA margin
    12.2%down 100 bps YoY
    FY25

    Due to higher costs including tariffs and increased investment in headcount.

    Net tariff impact
    $290 millionbetter than $325 million projected
    FY25

    Much of which was weighted in the second half of the year, better than projected due to timing of inventory deferrals.

    Capital expenditures
    $447 million
    FY25

    Included capacity expansion in Mexico kitting facility and continued investment in distribution centers.

    Net leverage
    3.1xdown from 4.9x at end of 2024
    End of 2025

    Reduced using IPO proceeds to pay down debt.

    IPO proceeds raised
    over $7 billion
    2025

    Strengthened financial position and bolstered financial flexibility.

    IPO proceeds used for debt paydown
    $4 billion
    2025

    Reduced net leverage from 4.9x to 3.1x.

    Medline Brand conversion for new prime vendor customers
    100% lift
    First year

    Refers to the increase in Medline Brand product penetration within new prime vendor accounts.

    Medline Brand convertible opportunity
    60%
    Ongoing

    Refers to the portion of total business that can be converted to Medline Brand products.

    Medline Brand convertible opportunity
    up to 80%
    Ongoing

    Refers to the portion of total business that can be converted to Medline Brand products.

    Medline Brand inventory on hand
    3 to 5 months
    Current

    Carried intentionally to provide high service levels to customers.

    Cost of manufacturing PPE in US
    3x to 7x
    Current

    Compared to manufacturing outside the United States, making domestic production challenging without significant incentives.

    Industry KPIs

    11
    MetricValueDetails
    System utilization—
    Pricing realized priceless than 50 bpsbps
    Market growth outgrowth—
    New product launch rampComfortTemp patient warming system
    Procedure volume growth—
    FCF conversion leverage guidance3.1xx
    Installed base system placements19facilities
    Segment franchise organic growth10%%
    Consumables recurring revenue mix—
    Sales force commercial capacity build—
    Indicated addressable patient population$25 billionUSD

    Product announcements

    2
    ProductTypeDetails
    ComfortTemp patient warming systemlaunch
    Mpowerlaunch

    Deals & partnerships

    8
    Microsoftpartnership

    Collaboration on Mpower, an AI-based digital supply chain control tower for prime vendor customers.

    Symboticpartnership

    Partnership to implement a pilot for bulk picking using AI-powered robotic technology in the Columbus, Ohio distribution center.

    Microtek Surgical Solutions (from Ecolab)acquisition

    Acquisition of the surgical business from Ecolab, which was lapped in the third quarter of 2025.

    Coloplastacquisition

    Acquisition of the skincare business, which was lapped in the fourth quarter of 2025.

    DiaMedacquisition$50 million

    Acquired in 2012 to enter the physician office space.

    ConvaTecacquisition

    Acquired the skin care line, which was a noncore asset for ConvaTec.

    Sinclair Dentalacquisition

    Acquired to test the dental market in Canada.

    PrefConnectacquisition

    Acquired a solution that provides Preference Card Management for customers.

    Risks & headwinds

    5
    Higher cost of goods due to tariffsFY25, FY26

    Net tariff impact of approximately $290 million in FY25; incremental $200 million tariff headwind expected in FY26.

    Mitigation: Shifting production across sourcing partners, optimizing internal manufacturing sites, leveraging U.S. FCA and Nairobi exemptions, implementing tariff price increases (August 2025).

    Increased investment in headcountQ4 FY25

    Contributed to Q4 FY25 adjusted EBITDA margin decline of 160 bps.

    Mitigation: Ongoing operational investments to drive growth.

    Potential moderation in healthcare utilization and procedure volumes2026

    Expected to moderate slightly relative to 2025.

    Mitigation: Focus on new customer signings and continued value delivery to customers.

    Fluidity of the tariff environmentOngoing

    Supreme Court decision related to IEEPA, new tariff rates (10% across the board effective yesterday), and high likelihood of additional tariff actions.

    Mitigation: Evaluating the impact, not reacting immediately, assessing the situation thoughtfully, and leveraging existing playbook for mitigation.

    Reimbursement profile challenges for healthcare customersOngoing

    Cuts in Medicaid, Medicare, concerns about the 'Big Beautiful Bill' and Affordable Care Act.

    Mitigation: Being a value player in the marketplace, helping customers with long-term financial viability, and serving all points across the continuum of care.

    Q&A highlights

    8

    What are hospital customers prioritizing in 2026, and what are the company's utilization expectations embedded in guidance?

    Hospitals are focused on reimbursement stabilization, value, navigating consolidation (especially to non-acute settings), and resilient supply chains. Medline serves all points of care. Utilization is expected to remain strong but moderate slightly in 2026 due to potential policy impacts.

    “health care is going through what I would call a crisis complexity right now. They're dealing with cuts in Medicaid, Medicare. They're worried about the one Big Beautiful Bill. They're concerned about what's happening with the Affordable Care Act.”

    asked by Elizabeth Anderson · answered by James Boyle

    2 min read6 chapters

    Detailed Narrative

    01

    Strategic Investments & Automation

    Medline continues to invest in enhancing its distribution network through automation and technology. The Colorado facility received its first AutoStore installation, and two California sites added their second, bringing the total to 19 U.S. facilities with over 2,100 robots for less-than-case picking. The company is also piloting a bulk picking solution with Symbotic in its Columbus, Ohio distribution center, leveraging AI-powered robotic technology to improve picking quality, accuracy, and speed for high-volume goods.

    02

    Customer Acquisition & Market Dynamics

    Medline achieved a record $2.4 billion in new customer signings in 2025, driven by its ability to deliver supply chain solutions and value. Major wins included the U.S. Department of Veterans Affairs and a large faith-based Integrated Delivery Network (IDN) that consolidated from five previous distributors to Medline. The company benefits from market conditions where customers seek value, stabilization in reimbursement, and resilient supply chain partners, especially with ongoing consolidation and the shift to non-acute care settings.

    03

    Medline Brand Product Portfolio Expansion

    The Medline brand product portfolio, comprising approximately 190,000 products, expanded with new innovations such as the ComfortTemp patient warming system. This forced-air warming blanket was designed to address limitations in existing solutions, making it easier for clinicians to position. The Medline Brand segment grew 10% in 2025, with volume gains from existing customers and conversions to Medline Brand products being key drivers.

    04

    Tariff Mitigation & Impact

    The net tariff impact🌐 for full year 2025 totaled approximately $290 million, which was better than the $325 million projected due to inventory deferrals. Medline implemented various mitigation strategies, including shifting production, optimizing internal manufacturing, and leveraging U.S. FCA and Nairobi exemptions. The company also implemented a tariff price increase in August 2025 to offset a portion of the burden, demonstrating resilience in a fluid tariff environment.

    05

    Financial Flexibility & Debt Reduction

    Medline closed 2025 with a successful IPO, raising over $7 billion, which significantly strengthened its financial position and bolstered flexibility. The company utilized $4 billion of the IPO proceeds to pay down debt, effectively reducing its net leverage from 4.9x at the end of 2024 to 3.1x at the end of 2025. This improved financial health positions Medline to invest in future growth and pursue strategic M&A opportunities.

    06

    Utilization Outlook and Product Opportunities

    While no immediate change in utilization has been observed, Medline anticipates a slight moderation in same-store sales growth for 2026 due to potential impacts from Medicare, Medicaid, and the Affordable Care Act. The company sees significant growth opportunities in surgical kitting, Lab & Diagnostics (a $25 billion market where Medline currently holds $1 billion), and the physician office segment (a $9 billion market with Medline's current $1.8 billion presence).

    AI-generated summary of the company’s earnings call. Not investment advice.